Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.
about
Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrationsDegradation of MEPE, DMP1, and release of SIBLING ASARM-peptides (minhibins): ASARM-peptide(s) are directly responsible for defective mineralization in HYPRegulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathwayIncreased renal catabolism of 1,25-dihydroxyvitamin D3 in murine X-linked hypophosphatemic ricketsThe significance of serum phosphate level on healing index and its relative effects in skeletally immature and mature patients with hypophosphatemic rickets.The changing face of hypophosphatemic disorders in the FGF-23 eraPharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia.A clinician's guide to X-linked hypophosphatemiaPregnane X receptor knockout mice display osteopenia with reduced bone formation and enhanced bone resorption.A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells.Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23.Approach to the hypophosphatemic patientCorrection of the mineralization defect in hyp mice treated with protease inhibitors CA074 and pepstatinThe chicken or the egg: PHEX, FGF23 and SIBLINGs unscrambled.CYP24 inhibition as a therapeutic target in FGF23-mediated renal phosphate wasting disorders1,25-Dihydroxyvitamin D Alone Improves Skeletal Growth, Microarchitecture, and Strength in a Murine Model of XLH, Despite Enhanced FGF23 Expression.Deformity correction in children with hereditary hypophosphatemic rickets.Therapeutic management of hypophosphatemic rickets from infancy to adulthood.The metabolic bone disease associated with the Hyp mutation is independent of osteoblastic HIF1α expression.Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment.Hypophosphatemic rickets: etiology, clinical features and treatment.Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG.A Mutation in the Dmp1 Gene Alters Phosphate Responsiveness in Mice.Abnormal regulation of renal vitamin D catabolism by dietary phosphate in murine X-linked hypophosphatemic rickets.Population pharmacokinetic and pharmacodynamic analyses from a 4-month intradose escalation and its subsequent 12-month dose titration studies for a human monoclonal anti-FGF23 antibody (KRN23) in adults with X-linked hypophosphatemia.Results of deformity correction in children with X-linked hereditary hypophosphatemic rickets by external fixation or combined technique.Hormonal Regulation of Osteocyte Perilacunar and Canalicular Remodeling in the Hyp Mouse Model of X-Linked Hypophosphatemia.Impact of Conventional Medical Therapy on Bone Mineral Density and Bone Turnover in Adult Patients with X-Linked Hypophosphatemia: A 6-Year Prospective Cohort Study.Magnetic Resonance Imaging Features as Surrogate Markers of X-Linked Hypophosphatemic Rickets Activity
P2860
Q24595718-03EB8892-E737-4ADA-B043-4B6D31C3A0ABQ24648401-85846D56-3ACB-4E66-9CC9-6CC374464CCEQ27026805-D9ED5C8E-CA8C-4615-BBB8-CED65C103245Q28361389-4BC75381-94B0-49D1-81DE-54508C11DEB0Q33598193-E03225E8-5B25-4CEA-8A40-557272C42FE4Q34221238-6E423A11-22FB-4EE3-BF68-A59507C8DF7CQ34480642-1E86BEAB-A8DB-4E4E-899A-BE413CBBBAD8Q35167526-A824698F-509E-4CB2-8F51-3115FA009AF6Q35765627-2F392B3A-DAB0-475A-97C4-DC4C38A68207Q35783146-156C53D3-6090-4F92-AF98-37149E6DDCD8Q35829300-D8068845-7EBE-44BB-98C0-1AEE66935F76Q35869678-A6B9BB50-332A-4FB2-8343-083FF318B6F4Q35983157-E5B2A831-27DE-41C5-8500-D3B460D4838AQ36074718-AB0008C4-E1BE-46A1-874C-AC0A13B22F68Q36515176-7086BA14-7EC9-464B-A0AA-CF2AA4E13712Q36889321-CBAD7A07-A78C-477D-82A4-3169C5822BA4Q37065868-1FA8A7A2-D385-42CC-8003-0EC5489EE559Q37648693-CD73275B-6F23-4DD4-B33F-E778EBACB4D5Q37720657-E26734E9-BCF0-44B4-9330-86932AC42179Q37958645-48C5A54B-4B0E-4695-A29B-CDDE551B0B21Q38222594-FA2D262B-460D-41A7-8486-9FA4F3084C94Q38700950-8D773DB8-5F80-4FB1-9C9D-7F15B99C7A18Q39074268-AE445364-E826-41FC-BACA-D8D6A1C837D4Q40347095-5A99E1D1-D64F-4E23-86C3-519C56FA90ECQ40654330-41D7C96D-06C6-4669-90BA-B1AD573D2558Q41119964-00A0E89C-46AA-4F28-830B-791B68C927EAQ47589028-9F5DAA53-444D-4060-872E-AE28C0B00B1DQ48295533-AB1C05EA-7427-4515-A98D-9B38D0D30DC4Q57736114-9D267D63-2ED4-4830-938A-46B8ADCF605F
P2860
Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol.
description
1985 nî lūn-bûn
@nan
1985 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1985 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1985年の論文
@ja
1985年論文
@yue
1985年論文
@zh-hant
1985年論文
@zh-hk
1985年論文
@zh-mo
1985年論文
@zh-tw
1985年论文
@wuu
name
Healing of bone disease in X-l ...... ith phosphorus and calcitriol.
@ast
Healing of bone disease in X-l ...... ith phosphorus and calcitriol.
@en
Healing of bone disease in X-l ...... ith phosphorus and calcitriol.
@nl
type
label
Healing of bone disease in X-l ...... ith phosphorus and calcitriol.
@ast
Healing of bone disease in X-l ...... ith phosphorus and calcitriol.
@en
Healing of bone disease in X-l ...... ith phosphorus and calcitriol.
@nl
prefLabel
Healing of bone disease in X-l ...... ith phosphorus and calcitriol.
@ast
Healing of bone disease in X-l ...... ith phosphorus and calcitriol.
@en
Healing of bone disease in X-l ...... ith phosphorus and calcitriol.
@nl
P2093
P2860
P356
P1476
Healing of bone disease in X-l ...... ith phosphorus and calcitriol.
@en
P2093
J M Harrelson
M K Drezner
N E Friedman
R M Harrell
P2860
P304
P356
10.1172/JCI111900
P407
P577
1985-06-01T00:00:00Z